Mr Yarwood will manage the business as Penn continues to expand and strengthens its services and international presence.
“Penn Pharma is a highly reputable business with a team of experienced and ambitious professionals who have succeeded in building an impressive international presence,” he said on his appointment.
“I am confident that I will be able to work competently with the team to further strengthen the business’s market presence and to ensure that Penn Pharma remains a well-known and well-respected name worldwide.”
Alongside the new CEO, David Cooper has also been appointed Operations Director having previously been General Manager of oral technologies at Zydis.
Penn Pharma was established more than three decades ago and provides worldwide integrated drug development, clinical trial supply and manufacturing services to the healthcare industry.